AstraZeneca Stock Forecast, Price & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 18.0% and is now trading at $52.61.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca or view MarketBeat's top 5 stock picks.

Wall Street analysts have given AstraZeneca a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstraZeneca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

AstraZeneca PLC (NYSE:AZN) released its quarterly earnings data on Tuesday, November, 10th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.03. The firm had revenue of $6.58 billion for the quarter, compared to analyst estimates of $6.65 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The company's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.99 earnings per share.
View AstraZeneca's earnings history.

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be paid a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date is Thursday, August 13th.
View AstraZeneca's dividend history.

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

11 Wall Street analysts have issued 1-year price objectives for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's stock price to reach $61.67 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for AstraZeneca.

AstraZeneca saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 6,050,000 shares, an increase of 20.3% from the October 15th total of 5,030,000 shares. Based on an average daily volume of 4,320,000 shares, the days-to-cover ratio is currently 1.4 days.
View AstraZeneca's Short Interest.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Sanofi (SNY), Sanofi (SNY), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK) and Zoetis (ZTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Walmart (WMT).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.18%), Fisher Asset Management LLC (0.66%), Arrowstreet Capital Limited Partnership (0.28%), BlackRock Inc. (0.26%), Winslow Capital Management LLC (0.22%) and Morgan Stanley (0.16%).
View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Arrowstreet Capital Limited Partnership, Epoch Investment Partners Inc., BlackRock Inc., Nuveen Asset Management LLC, Galibier Capital Management Ltd., PFM Health Sciences LP, and Point72 Asset Management L.P..
View insider buying and selling activity for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, BP PLC, Fisher Asset Management LLC, Lord Abbett & CO. LLC, Morgan Stanley, Acadian Asset Management LLC, OLD Mission Capital LLC, and Starr International Co. Inc..
View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $52.61.

AstraZeneca has a market capitalization of $138.08 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]